<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28262332</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>50</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.</ArticleTitle><Pagination><StartPage>7315</StartPage><EndPage>7327</EndPage><MedlinePgn>7315-7327</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.10.090</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)31205-1</ELocationID><Abstract><AbstractText>The third meeting of WHO's Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO's Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 World Health Organization. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giersing</LastName><ForeName>Birgitte K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vekemans</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nava</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaslow</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moorthy</LastName><ForeName>Vasee</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address: moorthyv@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>WHO Product Development for Vaccines Advisory Committee</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046129">Ebola Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022301">Herpes Simplex Virus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017780">Malaria Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D032581">Tuberculosis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046129" MajorTopicYN="N">Ebola Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022301" MajorTopicYN="N">Herpes Simplex Virus Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017780" MajorTopicYN="N">Malaria Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032581" MajorTopicYN="N">Tuberculosis Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bacterial</Keyword><Keyword MajorTopicYN="N">LMICs</Keyword><Keyword MajorTopicYN="N">PDVAC</Keyword><Keyword MajorTopicYN="N">Product development</Keyword><Keyword MajorTopicYN="N">SAGE</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Viral</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28262332</ArticleId><ArticleId IdType="pmc">PMC7131228</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.090</ArticleId><ArticleId IdType="pii">S0264-410X(16)31205-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. &lt;http://www.who.int/immunization_standards/vaccine_quality/TRS_978_61st_report_Annex_6_PQ_vaccine_procedure.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Tackling drug resistant infections globally: Final report and recommendation. &lt;http://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf&gt;.</Citation></Reference><Reference><Citation>Lipsitch M., Siber G.R. How can vaccines contribute to solving the antimicrobial resistance problem? MBio. 2016;7(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959668</ArticleId><ArticleId IdType="pubmed">27273824</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Vaccine Pipeline tracker. &lt;http://who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/&gt;.</Citation></Reference><Reference><Citation>Giersing Birgitte K, Modjarrad Kayvon, Moorthy Vasee S, WHO Product Development for Vaccines Advisory Committee (PDVAC) Pipeline Analyses for 25 Pathogens, vol. 34(26). p. 2863&#x2013;3006.</Citation><ArticleIdList><ArticleId IdType="pubmed">27108194</ArticleId></ArticleIdList></Reference><Reference><Citation>Weekly epidemiological record, 11 Dec 2015, No. 50, 2015, 90, 681&#x2013;700. &lt;http://www.who.int/wer/2015/wer9050.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Weekly epidemiological record 27 May 2016, No 21, 2016, 91, 265&#x2013;284. &lt;http://www.who.int/wer/2016/wer9121.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>O'Brien K, Binka F, Marsh K, Abramson JS. Mind the gap: jumping from vaccine licensure to routine use 2016;387(10031):1887&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27203633</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Vaccine Action Plan (GVAP). &lt;http://www.who.int/immunization/global_vaccine_action_plan/DoV_GVAP_2012_2020/en/&gt;.</Citation></Reference><Reference><Citation>SAGE GVAP Assessment Report 2015. &lt;http://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2015_EN.pdf&gt;.</Citation></Reference><Reference><Citation>Global TB Report 2015. &lt;http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>The End TB Strategy. &lt;http://www.who.int/tb/End_TB_brochure.pdf&gt;.</Citation></Reference><Reference><Citation>Knight G.M. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci USA. 2014;111(43):15520&#x2013;15525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4217399</ArticleId><ArticleId IdType="pubmed">25288770</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans T.G., Schrager L., Thole J. Status of vaccine research and development of vaccines for tuberculosis. Vaccine. 2016;34(26):2911&#x2013;2914. Evans PDVAC paper.</Citation><ArticleIdList><ArticleId IdType="pubmed">26973073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209&#x2013;2220.</Citation><ArticleIdList><ArticleId IdType="pubmed">19843557</ArticleId></ArticleIdList></Reference><Reference><Citation>&lt;https://www.niaid.nih.gov/news-events/first-new-hiv-vaccine-efficacy-study-seven-years-has-begun&gt;.</Citation></Reference><Reference><Citation>WHO World Malaria Report 2015: &lt;http://apps.who.int/iris/bitstream/10665/200018/1/9789241565158_eng.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7&#x2013;9th Sep 2015. Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS et al. Vaccine, 2016 Jun 3;34(26):2865&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130468</ArticleId><ArticleId IdType="pubmed">26993336</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaria vaccine roadmap: &lt;http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>WHO global consultation on universal influenza vaccines, August 2016. &lt;http://www.who.int/immunization/research/meetings_workshops/8th_influenza_vaccine_chicago2016/en/&gt;.</Citation></Reference><Reference><Citation>The Global Burden of Norovirus &amp; Prospects for Vaccine Development. &lt;http://collections.plos.org/norovirus&gt;.</Citation></Reference><Reference><Citation>Lopman B.A., Steele D., Kirkwood C.D., Parashar U.D. The vast and varied global burden of norovirus: prospects for prevention and control. PLoS Med. 2016;13(4):e1001999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846155</ArticleId><ArticleId IdType="pubmed">27115709</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.takeda.com/news/2016/20160620_7467.html.</Citation></Reference><Reference><Citation>Tate J.E., Burton A.H., Boschi-Pinto C. Global, regional, and national estimates of rotavirus mortality in children &lt;5 Years of Age, 2000&#x2013;2013. Clin Infect Dis. 2016;1(62 Suppl 2):S96&#x2013;S105.</Citation><ArticleIdList><ArticleId IdType="pubmed">27059362</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO guidance document for the quality, safety and efficacy of oral live attenuated rotavirus vaccines. &lt;http://www.who.int/biologicals/publications/trs/areas/vaccines/rotavirus/Annex%203%20rotavirus%20vaccines.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Lessa F.C., Gould C.V., McDonald L.C. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55(Suppl 2):S65&#x2013;S70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388017</ArticleId><ArticleId IdType="pubmed">22752867</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruyn G., Saleh J., Workman D. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized Phase 2 clinical trial. Vaccine. 2016;34(19):2170&#x2013;2178. 27.</Citation><ArticleIdList><ArticleId IdType="pubmed">27013431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheldon E., Kitchin N., Peng Y. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine. 2016;34(18):2082&#x2013;2091.</Citation><ArticleIdList><ArticleId IdType="pubmed">26993331</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;zay N., Ayad A., Dubischar K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585&#x2013;2592.</Citation><ArticleIdList><ArticleId IdType="pubmed">27079932</ArticleId></ArticleIdList></Reference><Reference><Citation>http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.</Citation></Reference><Reference><Citation>Zeng M., Mao X.H., Li J.X. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1457&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">26142048</ArticleId></ArticleIdList></Reference><Reference><Citation>Edited by M. Nesin, J. Read, M. Koso-Thomas, M. Brewinski Isaacs and A. Sobanjo-ter Meulen Advancing Maternal Immunization Programs through Research in Low and Medium Income Countries Volume 33, Issue 47, Pages 6371&#x2013;6502.</Citation></Reference><Reference><Citation>Nair H., Nokes D.J., Gessner B.D. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864404</ArticleId><ArticleId IdType="pubmed">20399493</ArticleId></ArticleIdList></Reference><Reference><Citation>http://www.uu.nl/en/news/first-consortium-of-local-manufacturers-to-make-affordable-biosimilars-available-for-low-income.</Citation></Reference><Reference><Citation>Kobayashia Miwako, Schrag Stephanie J, Vekemans Johan, Moorthy Vasee S. WHO consultation on Group B Streptococcus vaccine development: report from a meeting held on 27&#x2013;28 April 2016, Vekemans (in preparation).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892266</ArticleId><ArticleId IdType="pubmed">28017431</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Alignment of Immunization Safety Assessment in Pregnancy: &lt;https://brightoncollaboration.org/public/what-we-do/Projects/Gaia.html&gt;.</Citation><ArticleIdList><ArticleId IdType="pubmed">27751641</ArticleId></ArticleIdList></Reference><Reference><Citation>TB Vaccine Research &amp; Development: A Business Case for Investment. &lt;http://www.aeras.org/img/uploads/attachments/120/tb_vaccine_rd_business_case_2014_2.pdf&gt;.</Citation></Reference><Reference><Citation>Global Action Plan on Antimicrobial Resistance: &lt;http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Pendleton J.N., Gorman S.P., Gilmore B.F. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti-infective Ther. 2013;11(3):297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">23458769</ArticleId></ArticleIdList></Reference><Reference><Citation>Seale A.C., Davies M.R., Anampiu K. Invasive group A streptococcus infection among children, Rural Kenya. Emerg Infect Dis. 2016;22(2):224&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4734542</ArticleId><ArticleId IdType="pubmed">26811918</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A.S., Miller A.A., Donald R.G. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother. 2012;8(11):1585&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601133</ArticleId><ArticleId IdType="pubmed">22922765</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Health Sector Strategy on Sexually Transmitted Infections &lt;http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_33-en.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Gottlieb S.L., Deal C.D., Giersing B. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine. 2016;34(26):2939&#x2013;2947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759054</ArticleId><ArticleId IdType="pubmed">27105564</ArticleId></ArticleIdList></Reference><Reference><Citation>Looker K.J., Magaret A.S., Turner K.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE. 2015;10(1):e114989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301914</ArticleId><ArticleId IdType="pubmed">25608026</ArticleId></ArticleIdList></Reference><Reference><Citation>Looker K.J., Magaret A.S., May M.T. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS ONE. 2015;10(10):e0140765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624804</ArticleId><ArticleId IdType="pubmed">26510007</ArticleId></ArticleIdList></Reference><Reference><Citation>http://www.genocea.com/platform-pipeline/pipeline/gen003-for-genital-herpes/.</Citation></Reference><Reference><Citation>Newman L., Rowley J., Vander Hoorn S. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE. 2015;10(12):e0143304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672879</ArticleId><ArticleId IdType="pubmed">26646541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cates W., Jr., Washington A.E., Rubin G.L., Peterson H.B. The pill, chlamydia and PID. Fam Plann Perspect. 1985;17(4):175&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">3842809</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>http://ecdc.europa.eu/en/publications/Publications/07-06-2016-RRA-Enterovirus%2071-Spain.pdf.</Citation></Reference><Reference><Citation>WHO R&amp;D Roadmap: &lt;http://www.who.int/csr/research-and-development/WHO-R_D-Final10.pdf?ua=1&gt;.</Citation></Reference><Reference><Citation>Modjarrad K., Moorthy V.S., Ben Embarek P. A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat Med. 2016;22(7):701&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096003</ArticleId><ArticleId IdType="pubmed">27387881</ArticleId></ArticleIdList></Reference><Reference><Citation>Henao-Restrepo A.M., Preziosi M.P., Wood D. On a path to accelerate access to Ebola vaccines: the WHO's research and development efforts during the 2014&#x2013;2016 Ebola epidemic in West Africa. Curr Opin Virol. 2016;17:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524177</ArticleId><ArticleId IdType="pubmed">27180074</ArticleId></ArticleIdList></Reference><Reference><Citation>http://www.who.int/immunization/research/development/zika/en/.</Citation></Reference><Reference><Citation>Vannice K.S., Giersing B.K., Kaslow D.C. Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. Vaccine. 2019;37:7443&#x2013;7450.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916410</ArticleId></ArticleIdList></Reference><Reference><Citation>Black R.E., Cousens S., Johnson H.L. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969&#x2013;1987.</Citation><ArticleIdList><ArticleId IdType="pubmed">20466419</ArticleId></ArticleIdList></Reference><Reference><Citation>http://www.who.int/gho/immunization/en/.</Citation></Reference><Reference><Citation>Lanzieri T.M., Dollard S.C., Bialek S.R., Grosse S.D. Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. Int J Infect Dis. 2014;22:44&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829484</ArticleId><ArticleId IdType="pubmed">24631522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>